BioDelivery Sciences International, Inc. (NASDAQ:BDSI) – Investment analysts at Cantor Fitzgerald issued their FY2016 earnings estimates for shares of BioDelivery Sciences International in a report released on Tuesday. Cantor Fitzgerald analyst C. Russo anticipates that the firm will earn ($1.23) per share for the year. Cantor Fitzgerald has a “Hold” rating and a $3.00 price target on the stock. Cantor Fitzgerald also issued estimates for BioDelivery Sciences International’s FY2017 earnings at ($0.79) EPS.

A number of other equities research analysts also recently commented on the company. Zacks Investment Research downgraded BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Wednesday, October 19th. Janney Montgomery Scott raised BioDelivery Sciences International from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $2.45 to $4.00 in a research report on Friday, September 23rd. Roth Capital set a $6.00 price objective on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Monday, November 28th. Finally, FBR & Co reaffirmed a “buy” rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 20th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $5.14.

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

ILLEGAL ACTIVITY WARNING: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at http://www.watchlistnews.com/biodelivery-sciences-international-inc-bdsi-forecasted-to-post-fy2016-earnings-of-1-23-per-share/1060195.html.

BioDelivery Sciences International (NASDAQ:BDSI) traded down 1.282% on Friday, hitting $1.925. The stock had a trading volume of 48,959 shares. BioDelivery Sciences International has a 12-month low of $1.50 and a 12-month high of $4.39. The company’s 50 day moving average is $1.81 and its 200 day moving average is $2.28. The firm’s market cap is $104.18 million.

BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings data on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.04. BioDelivery Sciences International had a negative net margin of 93.61% and a negative return on equity of 309.49%. The business earned $3.60 million during the quarter, compared to analysts’ expectations of $3.58 million. During the same quarter in the previous year, the company posted ($0.39) EPS. The company’s revenue was up 200.0% compared to the same quarter last year.

Large investors have recently bought and sold shares of the stock. Bank of Montreal Can increased its stake in BioDelivery Sciences International by 2.2% in the third quarter. Bank of Montreal Can now owns 713,805 shares of the specialty pharmaceutical company’s stock worth $1,927,000 after buying an additional 15,515 shares during the period. Searle & CO. bought a new position in shares of BioDelivery Sciences International during the third quarter worth approximately $455,000. Krilogy Financial LLC bought a new position in shares of BioDelivery Sciences International during the second quarter worth approximately $164,000. Paloma Partners Management Co bought a new position in shares of BioDelivery Sciences International during the second quarter worth approximately $405,000. Finally, Parametric Portfolio Associates LLC boosted its position in shares of BioDelivery Sciences International by 1.2% in the second quarter. Parametric Portfolio Associates LLC now owns 807,097 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after buying an additional 9,727 shares in the last quarter. 51.28% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at http://www.watchlistnews.com/biodelivery-sciences-international-inc-bdsi-forecasted-to-post-fy2016-earnings-of-1-23-per-share/1060195.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.